Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Con

Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market

Needham analyst Serge Belanger initiates coverage on Evommune (NYSE:EVMN) with a Buy rating and a

Evommune, Inc. (NYSE: EVMN - Get Free Report) has been given a consensus recommendation of "Moderate

RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers th

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Compa

PALO ALTO, Calif., & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evomm

Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chroni

Oversold health care stocks: EVMN, NNNN, NAUT. RSI <30 shows they may be undervalued. EVMN drop

Evommune, Inc.'s recent miss with EVO756's CSU indications is a major setback. I agree that this cre

Evommune's CEO and CSO sold shares on June 22, 2026, under Rule 10b5-1 plans adopted months earlier

Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the compan

Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE:EVMN) with a Overweight and lowers

Wall Street analysts changed outlook on top names, including Alphine Income Property Trust, AAR Corp

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 284.8% to $11.39 during Monday

Read Also: Evommune Stock Cools Off After Big Rally On Successful Eczema Trial

Evommune said EVO756 failed to meet the primary endpoint in a Phase 2b CSU trial, ending development

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 poi

Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechn

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommu

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Evommune (NYSE:EVMN) with a Buy and

Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE:EVMN) with a Overweight and raises

Evommune (NYSE:EVMN) reported quarterly losses of $(0.64) per share which beat the analyst consensus

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Compa

 Up to 4,494,279 Shares of Common StockThis prospectus relates to the resale from time to time of up

Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist i

RBC Capital analyst Brian Abrahams reiterates Evommune (NYSE:EVMN) with a Outperform and maintain

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Compa

Capricorn Fund Managers Ltd acquired a new stake in Evommune, Inc. (NYSE: EVMN) in the fourth quarte

Top analysts changed outlook on top names. Mizuho, Needham, Rothschild & Co, HC Wainwright &

Wall Street analysts have changed their outlook on top names, with new coverage and price targets. S

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Evommune (NYSE:EVMN) with a Buy and

Clear Street analyst Kaveri Pohlman initiates coverage on Evommune (NYSE:EVMN) with a Buy rating

Shares of Evommune, Inc. (NYSE: EVMN - Get Free Report) have been assigned an average rating of "Mod

Clinical-stage biotech Evommune is seen as a potential buyout candidate. Its shares are up more than

Evommune (NYSE:EVMN) reported quarterly losses of $(1.43) per share which missed the analyst consens

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Compa

The Benzinga Stock Whisper Index highlights five stocks seeing strong interest from readers during t

Evommune, Inc. (NYSE: EVMN - Get Free Report) has earned a consensus rating of "Moderate Buy" from t

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (“Evommune” or the “Company”) (NYSE: E

Evommune, Inc. (NASDAQ: EVMN) shares are trading lower on Thursday on profit-taking after the stock

Evommune stock slips after a 70% rally on strong Phase 2 eczema data. Analysts raises success odds a

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Evommune (NYSE:EVMN) with a Buy and

The 70-patient trial was designed to evaluate the safety and efficacy of intravenous dosing of 5mg/k

Evommune shares jumped after its mid-stage trial showed strong skin improvement and good safety for